Literature DB >> 15947375

Highly active antiretroviral therapy.

Filip Moerman, Alfons Van Gompel, Jan Nimmegeers, Johan Moerman.   

Abstract

Mesh：

Year:  2005        PMID： 15947375      PMCID： PMC558269          DOI： 10.1136/bmj.330.7504.1341

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  14 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  Prevention of myocardial infarction.

Authors:  M R Adams
Journal:  Intern Med J       Date:  2002-12       Impact factor: 2.048

Review 3.  When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies.

Authors:  Andrew N Phillips; Alessandro Cozzi Lepri; Fiona Lampe; Margaret Johnson; Caroline A Sabin
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

4.  Elevated Framingham risk score in HIV-positive patients on highly active antiretroviral therapy: results from a Norwegian study of 721 subjects.

Authors:  B M Bergersen; L Sandvik; J N Bruun; S Tonstad
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-07-28       Impact factor: 3.267

5.  Is the time from HIV seroconversion a determinant of the risk of AIDS after adjustment for updated CD4 cell counts?

Authors: 
Journal:  J Acquir Immune Defic Syndr       Date:  2001-10-01       Impact factor: 3.731

6.  Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.

Authors:  Matthias Egger; Margaret May; Geneviève Chêne; Andrew N Phillips; Bruno Ledergerber; François Dabis; Dominique Costagliola; Antonella D'Arminio Monforte; Frank de Wolf; Peter Reiss; Jens D Lundgren; Amy C Justice; Schlomo Staszewski; Catherine Leport; Robert S Hogg; Caroline A Sabin; M John Gill; Bernd Salzberger; Jonathan A C Sterne
Journal:  Lancet       Date:  2002-07-13       Impact factor: 79.321

7.  Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999.

Authors:  F Bonnet; P Morlat; G Chêne; P Mercié; D Neau; I Chossat; M Decoin; F Djossou; J Beylot; F Dabis
Journal:  HIV Med       Date:  2002-07       Impact factor: 3.180

8.  Prevalence of hypertension in HIV-positive patients on highly active retroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients.

Authors:  B M Bergersen; L Sandvik; O Dunlop; K Birkeland; J N Bruun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-11-11       Impact factor: 3.267

9.  Combination antiretroviral therapy and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa M El-Sadr; Peter Reiss; Rodolphe Thiébaut; Linda Morfeldt; Stephane De Wit; Christian Pradier; Gonzalo Calvo; Matthew G Law; Ole Kirk; Andrew N Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2003-11-20       Impact factor: 91.245

Review 10.  Dyslipidaemia associated with antiretroviral therapy in HIV-infected patients.

Authors:  Leonardo Calza; Roberto Manfredi; Francesco Chiodo
Journal:  J Antimicrob Chemother       Date:  2003-11-25       Impact factor: 5.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.